Know Your Ports - Oncology Nursing News
Dec 21, 2017 · Throughout the course of treatment, many patients with cancer receive chemotherapy, intravenous fluids, antibiotics, and much more via central venous catheters such as Mediports.
Oncology Nursing News
Panelists discuss how amivantamab’s dual targeting of EGFR and MET may address resistance mechanisms and unmet needs in EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Dr Scott highlighting its potential clinical benefits, while Squires shares insights on managing the adverse event profile and strategies for managing adverse effects in patients receiving intravenous (IV ...
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
Nov 5, 2024 · SHR-A1921, a novel antibody-drug conjugate (ADC) demonstrated activity and safety for the treatment of patients with platinum-resistant ovarian cancer, according to data from a first-in-human phase 1 study (NCT05154604) that were presented during the 2024 ESMO Congress. 1 Evaluable patients treated with SHR-A1921 at a dose of 3.0 mg/kg once every 3 weeks (n = 26) experienced an overall ...
FDA Approves Zolbetuximab Regimen for Locally Advanced, …
Oct 18, 2024 · The FDA approved zolbetuximab-clzb (Vyloy) plus fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive and have not previously been treated. 1 The approval is based off findings from the randomized phase 3 ...
PD-L1 CPS Score Could Direct Treatment Decisions in Recurrent ...
Apr 1, 2022 · PD-L1 combined positive score (CPS) may serve to predict whether a patient with PD-L1–expressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) will receive optimal benefit with pembrolizumab (Keytruda) alone vs in combination with chemotherapy or with cetuximab (Erbitux) plus chemotherapy, according to an efficacy subgroup analysis of the phase 3 KEYNOTE-048 trial ...
Letter Warns Clinicians of Severe Infections With Pralsetinib for …
Nov 4, 2024 · Rigel Pharmaceuticals, the manufacturer of pralsetinib (Gavrelto) wrote a letter to healthcare providers warning about severe and fatal infection risks in patients with lung cancer observed with the drug in an ad-hoc analysis of the phase III AcceleRET-Lung trial (NCT04222972). 1,2 The FDA approved pralsetinib in August 2023 for patients with RET fusion-positive non-small cell lung cancer (NSCLC).
Belantamab Mafodotin, KRd Is Promising in Relapsed/Refractory …
Oct 2, 2024 · Belantamab mafodotin-blmf (Blenrep) plus carfilzomib, lenalidomide (Revlimid), and dexamethasone (a regimen known as KRd) demonstrated early evidence of deep responses, as well as a manageable adverse event profile in previously treated patients with multiple myeloma, according to data from a phase 1 trial (NCT04822337), presented at the 21st International Myeloma Society Annual Meeting. 1
Low-Dose Tamoxifen Shows Continued Efficacy in Adjuvant …
Feb 17, 2023 · Tamoxifen, at a dose of 5 mg daily (babytam), continued to show a benefit over placebo in reducing the risk of recurrence from invasive breast cancers and ductal carcinoma in situ (DCIS) in women with breast intraepithelial neoplasia in a 10-year follow-up of the TAM-01 trial (NCT01357772).
ASCO Recommends Abemaciclib for High-Risk HR+, HER2- Breast …
Oct 24, 2024 · The American Society of Clinical Oncology (ASCO) recently announced guidelines outlining a preference for abemaciclib (Verzenio) over ribociclib (Kisqali) for the treatment of patients with node-positive, high-risk, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. 1. The recommendation is based on findings from the monarchE (NCT03155997 ...
Opinion: The Media May Have Oversold AOH1996, City of Hope's …
Sep 20, 2023 · Early-phase clinical trials often involve medications that have not yet received their official names. Typically, these innovative drugs are given temporary names made up of a combination of numbers and letters while they are in development.